entertainment -WSS

entertainment

author：hotspot 2025-10-01 00:06:37 - browse：1348

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Do more moles mean more problems? Not so, says new study

WSS

Health insurers say they are turning to AI to cut costs, improve care

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Focused ultrasound for uterine fibroids: an uphill battle

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

What will save rural psychiatry services? Higher Medicaid payments

hotspot

entertainment

explore

Medical records are filled with copy

What Mike Pence has said that could be used in a Donald Trump trial

Sports medicine is finally prioritizing gender equality

Report: NIH

Hepatitis C has a cure — but many Americans still lack access to it

Do more moles mean more problems? Not so, says new study

The cancer drug shortage isn’t new — and neither are the solutions

Dark money group runs ads on China biotech bill

The high cost of giving birth even with insurance

What will save rural psychiatry services? Higher Medicaid payments

Wikipedia

Focused ultrasound for uterine fibroids: an uphill battle

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

What Mike Pence has said that could be used in a Donald Trump trial

Akili, maker of video game for ADHD, to be acquired for 34 million

Scientists successfully use ultrasound imaging to map brain activity

What Henrietta Lacks settlement says about racism in medicine

entertainment

hotspot

knowledge

focus